|
| Oncology Tumor Experience |
| |
 |
51 Oncology trials conducted since 2001 |
|
Total of 6,398 patients accrued |
|
Trials conducted: |
| |
 |
Phase I – 2 trials |
| |
|
Phase II – 22 trials |
| |
|
Phase III – 15 trials |
| |
|
Phase IV – 6 trials |
| |
|
Tumor Types include: |
| |
|
 |
Breast |
| |
|
|
CLL |
| |
|
|
NSCLC |
| |
|
|
Non
Hodgkin’s Lymphoma |
| |
|
|
Colorectal |
| |
|
|
Hodgkin’s Lymphoma |
| |
|
|
Prostate |
| |
|
|
Melanoma |
| |
|
|
SCLC |
| |
|
|
Multiple Myeloma |
| |
|
|
Renal |
| |
|
|
MDS |
| |
|
|
Head & Neck |
| |
|
|
Glioblastoma |
| |
|
|
Bone Mets |
|
| Tumor Experience |
| |
| CANCER |
Phase |
Number of Patients |
Number of Sites |
Year |
| Breast cancer |
IV |
300 |
70 |
2001 |
| Breast--1st line Met |
II |
51 |
21 |
2003 |
| Breast--1st line Met |
II |
72 |
29 |
2004 |
| Breast--Adjuvant ER+ |
III |
117 |
8 |
2006 |
| Breast--2nd line Met |
III |
7 |
14 |
2006 |
| Breast--1st line Met |
III |
17 |
14 |
2006 |
| Breast--1st line Met |
II |
10 |
15 |
2007 |
| Breast--1st line Met |
II |
3 |
14 |
2008 |
| Breast 1st/2nd line Met |
II |
0 |
5 |
2008 |
| NSCLC |
II b |
110 |
20 |
2003 |
| NSCLC 1st line |
II |
82 |
21 |
2004 |
| NSCLC 2nd line |
II |
7 |
9 |
2004 |
| NSCLC 1st line |
II |
69 |
22 |
2005 |
| NSCLC 2nd
line |
II |
70 |
20 |
2005 |
| NSCLC 1st
line |
II |
43 |
29 |
2006 |
| Lung |
Epidemiology |
3000 |
65 |
2006 |
| NSCLC 1st
line |
III |
15 |
4 |
2006 |
| Advanced
NSCLC |
II |
10 |
8 |
2007 |
| NSCLC 2nd &
3rd line |
III |
6 |
12 |
2007 |
| SCLC 2nd
line |
III |
5 |
9 |
2008 |
| Rectum |
II |
87 |
16 |
2003 |
|
Colorectal--1st line Met |
II |
82 |
19 |
2004 |
|
Colorectal--1st line Met |
III |
57 |
31 |
2205 |
|
Colorectal--2nd line Met |
II |
29 |
39 |
2006 |
| Prostate |
III a |
250 |
50 |
2002 |
| Prostate |
IV |
160 |
50 |
2003 |
| Prostate |
IV |
85 |
12 |
2004 |
| HRPC--1st
line |
II |
35 |
22 |
2006 |
| Prostate |
Epidemiology |
120 |
1 |
2007 |
| Prostate |
II a |
24 |
6 |
2007 |
| HRPC--1st
line |
III |
11 |
10 |
2007 |
|
Prostate--2nd line Met or beyond |
EAP |
40 |
16 |
2007 |
| Kidney |
I |
10 |
5 |
2004 |
| Renal
cell--1st line Met |
III |
41 |
11 |
2006 |
| Kidney |
Epidemiology |
35 |
1 |
2008 |
| Hodgkins
Lymphoma |
I |
15 |
1 |
2006 |
| NHL |
III |
320 |
42 |
2007 |
| CLL |
IV |
210 |
25 |
2007 |
| MDS |
II |
15 |
13 |
2004 |
| Biliary
tract |
II |
61 |
6 |
2003 |
|
Melanocarcinoma |
II a |
152 |
2 |
2007 |
| Melanoma |
II |
7 |
8 |
2007 |
| Cancer |
Pharmacovigilance |
N/A |
N/A |
2007 |
| Head and
Neck |
Investigator-initiated study |
75 |
1 |
2007 |
| Glioblastoma |
IV |
150 |
12 |
2000 |
| Myeloma |
IV |
300 |
60 |
2001 |
| Multiple
Myeloma –1st line |
IIIb |
7 |
17 |
2007 |
| Supportive
Care--Antiemetic Breast, NSCLC, Colon |
II |
33/16 |
14 |
2006 |
| Supportive
Care--NSCLC Chemo-induced Thrombocytopenia |
III |
0 |
5 |
2006 |
| Supportive
Care—Breast, Bone Met |
III |
3 |
12 |
2006 |
| Supportive
Care--Bone Mets |
III |
23 |
8 |
2006 |
|
| |
